Advertisement

Clinical Research in France, Europe, and in the World Dedicated to Ovarian Cancers

Chapter
  • 939 Downloads

Abstract

Clinical research in Gynecology Oncology (GYN) has succeeded to run these last years a series of large trials, thanks to its unique organization in networks from the country to the worldwide level. At the country level, national/regional cooperative groups have multiplied and reached to date the number of 27. These GYN cooperative groups are currently found in North/Central America, Western and more recently Eastern Europa, Middle East, and Asia, including Japan, China, and Korea. At the continent level, ENGOT (European Network of Gynecology Oncology Trials) is the European model of cooperation between groups. GYN groups from all the continents (with the sad exception of Africa) are gathered in GCIG (Gynecologic Cancer InterGroup)

Keywords

Ovarian Cancer Endometrial Cancer Translational Research Gynecological Cancer Cooperative Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l’Etude des Cancers Ovariens phase II study. Semin Oncol. 1997;24(5 Suppl 15):S15-30–5.Google Scholar
  2. 2.
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Falandry C, Weber B, Savoye AM, Tinquaut F, Tredan O, Sevin E, Stefani L, Savinelli F, Atlassi M, Salvat J, Pujade-Lauraine E, Freyer G. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol. 2013;24(11):2808–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A, European Network of Gynaecological Oncological Trial Groups. European network of gynaecological oncological trial groups’ requirements for trials between academic groups and pharmaceutical companies. Int J Gynecol Cancer. 2010;20(3):476–8.CrossRefPubMedGoogle Scholar
  7. 7.
    du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, Del Campo J, Calvert P, Aravantinos G, Vardar MA, van der Zee AG, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I, Member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT). European network of gynaecological oncological trial groups’ requirements for trials between academic groups and industry partners--first update 2015. Int J Gynecol Cancer. 2015;25(7):1328–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Vergote I, Elser G, Votan B, Farrelly L, De Roover J, Bryce J, du Bois A, member trial groups of the European Network of Gynaecological Trial groups (ENGOT). Roadmap for the European network of gynaecological trial groups (ENGOT) trials. Int J Gynecol Cancer. 2013;23(7):1339–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Marth C, du Bois A, Schauer C, du Bois A, Casado A, Vergote I, del Campo JM, Goudopoulou A, Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Chekerov R, Raza Mirza M, Westermann A, Glasspool R, Taskiran C, Fehr M, Cibula D. The European network for gynaecological oncological trial groups Charta for privileged partnership. Int J Gynecol Cancer. 2015;25(6):1094–5.PubMedGoogle Scholar
  10. 10.
    Quinn M. Developing an international network for clinical research: the gynecological cancer intergroup experience. Clinical Investigation. 2012;2(1):29–33.CrossRefGoogle Scholar
  11. 11.
    Bacon M, Kitchener H, Stuart GC, Vermorken JB, Gynecologic Cancer InterGroup and participants of 4th Ovarian Cancer Consensus Conference. The global impact of the gynecologic cancer InterGroup in enhancing clinical trials in ovarian cancer. Int J Gynecol Cancer. 2011;21(4):746–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Stuart GC, Kitchener H, Bacon M, du Bois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E, participants of 4th Ovarian Cancer Consensus Conference (OCCC); Gynecologic Cancer Intergroup. 2010 gynecologic cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer. 2011;21(4):750–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY, McCormack M, Plante M, Casado A, Reuss A, Chávez-Blanco A, Kitchener H, Nam BH, Jhingran A, Temkin S, Mileshkin L, Berns E, Scholl S, Doll C, Abu-Rustum NR, Lecuru F, Small Jr W, participants of the Gynecologic Cancer InterGroup Cervix Cancer brainstorming day. Advances and concepts in cervical cancer trials: a road Map for the future. Int J Gynecol Cancer. 2016;26(1):199–207.CrossRefPubMedGoogle Scholar
  14. 14.
    Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J, Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N. Gynecologic cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S42–7.CrossRefPubMedGoogle Scholar
  16. 16.
    McAlpine JN, Greimel E, Brotto LA, Nout RA, Shash E, Avall-Lundqvist E, Friedlander ML, Joly F, Gynecologic Cancer InterGroup (GCIG). Quality of life research in endometrial cancer: what is needed to advance progress in this disease site? Methodological considerations from the gynecologic cancer InterGroup symptom benefit working group brainstorming session, Leiden 2012. Int J Gynecol Cancer. 2014;24(9):1686–92.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.AP-HPHôtel-Dieu, Centre des cancers de la femmeParisFrance
  2. 2.Centre François Baclesse, Avenue du Général HarrisCAENFrance
  3. 3.Centre CARIO - HPCAPLERIN-SUR-MERFrance
  4. 4.Centre Léon BérardUniversité Claude BernardLyonFrance
  5. 5.Chirurgie cancérologiqueHEGPParisFrance
  6. 6.Département Hémato-OncologieHôpitaux Universitaires de StrasbourgSTRASBOURGFrance

Personalised recommendations